Jong Chul Park1, T Martin Ma2, Lisa Rooper3, Todd Hembrough4, Robert D Foss5, Nicole C Schmitt6, Rishi Sawhney7, Aaron Flanders8, Hyunseok Kang2. 1. Department of Medicine, Harvard Medical School and Massachusetts General Hospital, Boston, Massachusetts. 2. Department of Oncology, The Johns Hopkins University School of Medicine, Baltimore, Maryland. 3. Department of Pathology, The Johns Hopkins University School of Medicine, Baltimore, Maryland. 4. NantOmics, Rockville, Maryland. 5. Department of Dermatology, The Johns Hopkins University School of Medicine, Baltimore, Maryland. 6. Department of Otolaryngology - Head and Neck Surgery, The Johns Hopkins University School of Medicine, Baltimore, Maryland. 7. Bayhealth Cancer Institute, Dover, Maryland. 8. Department of Hematology/Oncology, Naval Medical Center, Portsmouth, Virginia.
Abstract
BACKGROUND: Alterations in the human epidermal growth factor receptor-2 (HER2) pathway have been identified in a subset of salivary duct carcinomas. Dual HER2 inhibition with trastuzumab and pertuzumab has superior antitumor efficacy to trastuzumab monotherapy in HER2-positive breast cancer, yet its efficacy in HER2-positive salivary duct carcinoma is unknown. METHODS: We report 2 cases of exceptional responses of HER2-positive salivary duct carcinomas to dual HER2 blockade and docetaxel combination and their molecular characteristics. RESULTS: A 54-year-old man with recurrent metastatic HER2 expressing salivary duct carcinoma of the parotid gland after definitive concurrent chemoradiation achieved a complete response (CR) after 6 cycles of trastuzumab, pertuzumab, and docetaxel (TPH). A 42-year-old woman with HER2-positive salivary duct carcinoma of the parotid gland with bone and liver metastases had CR with TPH and remains in remission on maintenance trastuzumab and pertuzumab. CONCLUSION: Dual HER2 blockage resulted in CR in patients with HER expressing salivary duct carcinoma and warrants further evaluation in this patient population.
BACKGROUND: Alterations in the humanepidermal growth factor receptor-2 (HER2) pathway have been identified in a subset of salivary duct carcinomas. Dual HER2 inhibition with trastuzumab and pertuzumab has superior antitumor efficacy to trastuzumab monotherapy in HER2-positive breast cancer, yet its efficacy in HER2-positive salivary duct carcinoma is unknown. METHODS: We report 2 cases of exceptional responses of HER2-positive salivary duct carcinomas to dual HER2 blockade and docetaxel combination and their molecular characteristics. RESULTS: A 54-year-old man with recurrent metastatic HER2 expressing salivary duct carcinoma of the parotid gland after definitive concurrent chemoradiation achieved a complete response (CR) after 6 cycles of trastuzumab, pertuzumab, and docetaxel (TPH). A 42-year-old woman with HER2-positive salivary duct carcinoma of the parotid gland with bone and liver metastases had CR with TPH and remains in remission on maintenance trastuzumab and pertuzumab. CONCLUSION: Dual HER2 blockage resulted in CR in patients with HER expressing salivary duct carcinoma and warrants further evaluation in this patient population.
Authors: Ruta Gupta; Mark J Cowley; Simon A Mueller; Marie-Emilie A Gauthier; James Blackburn; John P Grady; Spiridoula Kraitsek; Elektra Hajdu; Matthias S Dettmer; Jane E Dahlstrom; C Soon Lee; Peter P Luk; Bing Yu; Roland Giger; Sarah Kummerfeld; Jonathan R Clark Journal: Mod Pathol Date: 2020-05-26 Impact factor: 7.842
Authors: Chiara Focaccetti; Monica Benvenuto; Sara Ciuffa; Sara Fazi; Manuel Scimeca; Alessandra Nardi; Martino Tony Miele; Andrea Battisti; Elena Bonanno; Andrea Modesti; Laura Masuelli; Roberto Bei Journal: Nutrients Date: 2020-05-14 Impact factor: 5.717
Authors: Wim van Boxtel; Gerald W Verhaegh; Ilse A van Engen-van Grunsven; Dianne van Strijp; Leonie I Kroeze; Marjolein J Ligtenberg; Hans B van Zon; Yara Hendriksen; Diederick Keizer; Anja van de Stolpe; Jack A Schalken; Carla M van Herpen Journal: Int J Cancer Date: 2019-12-12 Impact factor: 7.396